#57 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to recognize cannabis use disorder as a legitimate diagnosis with increasing clinical relevance as modern cannabis products contain significantly higher THC concentrations than historical preparations, making dependence more likely in vulnerable patients. Understanding evidence-based treatment approaches for cannabis use disorder enables clinicians to provide appropriate interventions for the growing population of patients seeking help with problematic use, potentially reducing psychiatric comorbidities and improving treatment outcomes.
Cannabis use disorder (CUD) is a recognized DSM-5 diagnosis with increasing clinical relevance as cannabis potency has substantially increased over recent decades, making dependence and withdrawal syndromes more common and severe than in previous generations. Modern cannabis products, particularly concentrated forms and high-THC strains, carry greater risks for addiction compared to historical cannabis use, necessitating updated clinical awareness and screening practices. Clinicians should recognize that CUD presents with genuine physiological and psychological withdrawal symptoms when patients attempt cessation, including irritability, sleep disturbance, anxiety, and decreased appetite, which warrant supportive management rather than dismissal as merely behavioral issues. Evidence-based treatment approaches include cognitive-behavioral therapy, motivational interviewing, and in some cases pharmacological support, though no FDA-approved medications specifically target cannabis dependence. Understanding the spectrum of cannabis use disorder and its modern manifestations enables clinicians to identify at-risk patients, assess severity, and offer appropriate interventions that improve treatment engagement and outcomes. Clinicians should screen for CUD in patients with regular cannabis use and be prepared to discuss the relationship between product potency and addiction risk when counseling patients on safer use or cessation strategies.
“Cannabis use disorder is indeed recognized in the DSM-5 and represents a genuine clinical condition we see in practice, though it affects a smaller percentage of users than many assume. The potency question is real from a pharmacology standpoint, but what matters most clinically is matching evidence-based interventions like cognitive-behavioral therapy and motivational interviewing to each person’s specific pattern of use and underlying drivers for dependence.”
💊 Cannabis use disorder, now formally recognized in the DSM-5, presents clinicians with a growing patient population seeking help, particularly as modern cannabis products contain significantly higher THC concentrations and novel delivery methods compared to previous decades. The increasing potency and availability of cannabis products have likely contributed to rising rates of problematic use, though individual vulnerability to addiction involves complex interactions between genetics, mental health comorbidities, age of initiation, and frequency of use that vary considerably among patients. While evidence-based treatments such as cognitive behavioral therapy, motivational interviewing, and contingency management show promise, cannabis use disorder remains understudied compared to other substance use disorders, and pharmacological interventions remain limited. Clinicians should routinely screen for cannabis use, particularly in adolescents and young adults, assess for withdrawal symptoms and functional impairment rather than relying solely on frequency of use, and recognize that many patients with cannabis use disorder also have underlying anxiety
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
